Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Rating)’s stock price traded down 4% on Monday . The stock traded as low as $0.38 and last traded at $0.38. 1,770 shares were traded during trading, a decline of 83% from the average session volume of 10,186 shares. The stock had previously closed at $0.40.
Antibe Therapeutics Stock Performance
The firm has a 50-day moving average price of $0.41 and a two-hundred day moving average price of $0.40.
Antibe Therapeutics (OTCMKTS:ATBPF – Get Rating) last released its quarterly earnings data on Tuesday, February 14th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. On average, equities research analysts predict that Antibe Therapeutics Inc. will post -0.3 EPS for the current year.
About Antibe Therapeutics
Antibe Therapeutics, Inc is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places.
Featured Articles
- Get a free copy of the StockNews.com research report on Antibe Therapeutics (ATBPF)
- Medtronic: Reversal In-Play For This High-Yield Stock
- Is it ‘Game Over’ for Roblox After Reporting March Metrics Miss?
- Is it Time to Take Profits in Chip Stocks?
- Will Stratasys Continue to be a Runaway Bride?
- Garrett Motion Inc. Skids on Results: Is it Time to Buy the Dip?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
